뉴스&공지

공지

ANL-104, a treatment for degenerative obesity and diabetes, registered as a domestic patent

2021-01-19

The domestic patent registration of ANL-104, a candidate substance for the treatment of degenerative metabolic diseases of ANLBIO Co., Ltd., was decided on January 15.


'ANL-104' is a gene therapy that promotes body fat decomposition by enhancing the expression of target proteins in a way that inhibits certain microRNAs (microRNAs) that increase with aging, and is currently in the preclinical stage as a major indication of degenerative obesity and diabetes.


Target proteins that increase expression by administration of 'ANL-104' are known to have excellent lipolysis effects. Through animal experiments conducted with external specialized institutions, the company confirmed that the treatment injected into the hypothalamus increased the expression of the protein, significantly reducing fat as well as weight and blood sugar, and this registered patent was filed in 2017 based on the above results of these animal tests.      


With the completion of the domestic patent registration of ANL-104, a candidate for degenerative obesity and diabetes treatment, along with ANL-101, which was selected as a dementia treatment project by the Dementia Overcoming Research and Development Project in December, it is expected to gain further momentum.   


Given the rapidly aging population structure, the company's medical demand for degenerative diseases such as dementia, obesity, and diabetes is expected to increase sharply in the future.


We will make efforts to help ANLBIO advance the treatment of dementia diseases such as Alzheimer's disease and Parkinson's disease, as well as numerous diseases that hinder the quality of life with age, such as degenerative metabolic diseases of ANL-104.